Retaane Fails Again In Macular Degeneration
This article was originally published in The Pink Sheet Daily
Executive Summary
Alcon halts program after large risk-reduction trial disappoints.
You may also be interested in...
Genentech Posts Solid Second Quarter
EPS misses consensus, but sales of most products modestly estimates.
Novartis To Acquire Majority Stake In Alcon
Deal offers synergies with firm’s Ciba Vision affiliate and ex-U.S. marketing rights to Lucentis.
QLT Divests U.S. Business, Retains Wet AMD Treatment Visudyne
Following a strategic review of its assets, Canadian company divests its only other marketed product, prostate cancer drug Eligard, and lays off 115 employees.